Trial Profile
Efficacy and safety of concurrent chemoradiotherapy combined with Nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Oct 2018 New trial record
- 01 Sep 2018 Results published in the Medicine